AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ATOSSA THERAPEUTICS, INC. Director's Dealing 2025

May 16, 2025

34113_dirs_2025-05-16_867fa953-d1a1-467d-ac44-22c8f7925774.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ATOSSA THERAPEUTICS, INC. (ATOS)
CIK: 0001488039
Period of Report: 2025-05-15

Reporting Person: Chen Shu-Chih (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-15	Stock Option (right to buy)	$0.99	A	125000	Acquired	2035-05-15	Common Stock (125000)	Direct

Footnotes

F1: The options shall vest on a quarterly basis over 12 months following May 15, 2025, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued on May 15, 2025 with an exercise price of $0.99, representing the closing stock price on May 15, 2025.